Healing outcomes after placental membrane-based skin substitute allografts in multiple wound types in routine care: a retrospective case series from a prospective observational wound registry.

BACKGROUND: Real-world data on cellular, acellular, and matrix-like products (CAMPs) remain limited, particularly in mixed-etiology cohorts. OBJECTIVE: To describe routine practice hard-to-heal wound healing outcomes among adults treated with placental membrane-based allografts. METHODS: This retrospective case series drew on a prospective observational wound registry. Eligible adults had at least 1 application of a placental-derived CAMP and 1 follow-up visit. One index wound per patient was selected for primary analyses; secondary summaries covered all wounds. The primary endpoint was complete closure by 12 weeks; secondary endpoints were time to closure, at least 50% area reduction at 4 weeks, and percentage area reduction (PAR) at 12 weeks among open wounds. RESULTS: The cohort included 44 patients with 60 CAMP-treated wounds; 75.0% of index wounds were lower extremity diabetic ulcers (LEDUs), and median baseline duration was 91 days. Closure by 12 weeks occurred in 17 of 44 index wounds (38.6%; 95% CI, 24.4%-54.5%) and 22 of 60 wounds (36.7%; 95% CI, 24.6%-50.1%). Median time to closure among healed wounds was 28 days. At 4 weeks, 52.3% of index and 56.7% of all wounds achieved at least 50% area reduction. Among open wounds at 12 weeks, median PAR was 48.8% (index) and 50.8% (all). In a complete-case subset, 22 of 26 wounds closed (84.6%; 95% CI, 65.1%-95.6%), interpreted cautiously because wounds without ascertainable 12-week status were excluded. CONCLUSIONS: Findings in this cohort, most with LEDUs and substantial comorbidity burden, provide pragmatic benchmarks for CAMP-treated wounds and support the need for larger, standardized comparative studies.